BIOMAT Database Logo BIOMAT Database Logo

Comparison of different antibodies for detection of progesterone receptor in breast cancer. 2002

Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA.

Monoclonal antibodies directed against human estrogen receptor (ER) and progesterone receptor (PR) have been used extensively for biochemical and immunohistochemical detection of receptors independent of hormone-binding assays. These antibodies have been valuable both for experimental work and for detection of receptors in clinical breast cancer specimens. The purpose of this study was to characterize the sensitivity and specificity of different antibodies for detection of PR by immunohistochemistry (IHC) of formalin-fixed paraffin breast carcinoma sections. The panel of twelve antibodies included two new ones (PgR636 and PgR1294) produced prospectively to be resistant to formalin fixation and paraffin embedding. Fifty-nine breast carcinomas, having known PR levels by biochemical ligand-binding assay, were used to prepare multitumor paraffin-embedded tissue blocks for characterization of the PR antibodies. Of all the antibodies tested, both PgR636 and PgR1294 stained the highest percentage of breast carcinomas known to be positive by the biochemical assay (95-98%) and they exhibited the highest concordance with the biochemical assay (88-90%). The PgR636 and PgR1294 antibodies, along with one other, PR 88, also gave the highest intensity of nuclear staining, while PgR636 and PgR1294 stained the highest mean percentage of tumor cell nuclei. Antigen retrieval was not necessary for PR immunostaining by PgR636 and PgR1294 in most tumors and other tissues examined, but did slightly increase the staining intensity. The majority of the other antibodies tested were highly dependent on antigen retrieval; only PR 88 and KD 68 antibodies approached the performance of PgR636 and PgR1294 without antigen retrieval. These results indicate that PgR636 and PgR1294 are optimal antibodies for IHC detection of PR in routine paraffin tissue blocks.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Immunocytochemical detection of progesterone receptor in breast carcinoma. Comparison of two monoclonal antibodies.
March 1990, American journal of clinical pathology,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
[Comparative immunohistochemistry study of different antibodies clones for detection of breast cancer markers (estrogen receptor, progesterone receptor, HER2/neu, Ki-67)].
January 2024, Arkhiv patologii,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
[Immunohistochemical detection of estrogen and progesterone receptors in breast cancer using monoclonal antibodies: comparison with biochemical receptor analysis].
January 1989, Der Pathologe,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system.
January 2014, International journal of clinical and experimental pathology,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Monoclonal antibodies for progesterone receptor assays and polymorphism studies in breast cancer. Comparison with radioligand assays.
January 1988, Bulletin du cancer,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
[Immunohistochemical detection of progesterone receptors in breast cancer. Comparison of antibodies mPRI and PR-ICA].
March 1990, Der Pathologe,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
August 2018, Annals of diagnostic pathology,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
[Antibodies in the immunohistochemical detection of estrogen and progesterone receptor status in breast carcinoma].
April 2015, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
March 2018, Applied immunohistochemistry & molecular morphology : AIMM,
Michael Press, and Betsy Spaulding, and Susan Groshen, and David Kaminsky, and Margaret Hagerty, and Lori Sherman, and Kurt Christensen, and Dean P Edwards
Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
September 2008, Breast cancer research and treatment,
Copied contents to your clipboard!